PhD Scientific Days 2022

Translational Medicine II. (Poster discussion will take place in the Aula during the Coffee Break)

A Cannabis sativa special extract, that can treat spasticity of multiple sclerosis: a systematic review and meta-analysis

Előadó neve

Dr. Kleiner, Dénes

Előadó munkahelye

University Pharmacy Department of Pharmacy Administration & Centre for Translational Medicine, Semmelweis University, Budapest, Hungary

Előadó telefonszáma

+36208250325

Előadó e-mail címe

deneskleiner@gmail.com

Az előadás címe

A Cannabis sativa special extract, that can treat spasticity of multiple sclerosis: a systematic review and meta-analysis

Szerző(k) neve és munkahelye

Dénes Kleiner1;2, István Horváth1;2, Stefania Bunduc2;3;4;5;6, Dorottya Gergő2;7, Katalin Lugosi2, Peter Fehérvári2;8, Peter Hegyi2;3;4;9, Tamás Horváth2, Dezső Csupor2;10;11
1 University Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary
2 Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
3 Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
4 Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
5 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
6 Fundeni Clinical Institute, Bucharest, Romania
7 Department of Pharmacognosy, Semmelweis University, Budapest, Hungary
8 University of Veterinary Medicine, Budapest Dept. Of Biomathematics and Informatics, Budapest, Hungary
9 János Szentágothai Research Center, University of Pécs, Pécs, Hungary
10 Department of Clinical Pharmacy, University of Szeged, Szeged, Hungary
11 Department of Pharmacognosy, University of Szeged, Szeged, Hungary

Bemutatás módja

Poszter

Szekció

Translational Medicine II. (Poster discussion will take place in the Aula during the Coffee Break)

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction:
About 2.8 million people live with multiple sclerosis worldwide, and more than a quarter suffer from spasticity refractory to standard treatment. Nabiximols, a well characterized Cannabis sativa extract as an add-on agent may alleviate spasticity in these cases.
Aims:
The aim of our study was to investigate the efficacy of nabiximols in the alleviation of multiple sclerosis-associated spasticity in the meta-analysis of randomized clinical trials.
Method:
We followed the recommendation of Cochrane collaborations, and the protocol was preregistered to PROSPERO (CRD42021282177). The systematic search was performed on 2021.10.15. in 5 medical databases. The primary outcome was responder rate by spasticity numerical rating scale. The evaluated intervention consisted of nabiximols besides standard treatment in patients with refractory spasticity. The comparator was standard treatment alone and placebo. Spasticity-related other parameters were measured as secondary outcomes. We estimated pooled mean differences or odds ratios and associated 95% confidence intervals (95%CI).
Results:
We identified 9 eligible randomized controlled trials comprising 1451 patients in double-blind studies. With our primary outcome, we confirmed that at least two times more people will respond well to nabiximols than placebo (OR = 2.41, 95% CI = 1.39; 4.18, p < 0.01). On the other hand, heterogeneity was high, as only 5 studies could have been included to this estimation with an I2 of 68% (p = 0.01). The secondary outcomes were also in accordance with the primary outcome.
Conclusion:
Our present meta-analysis confirms the utility of nabiximols in therapy-resistant spasticity of multiple sclerosis. While several limitations (eg. the lack of comparison with other agents, relatively high heterogeneity) can influence the weight of our results and side effects can have negative effect on the cost-benefit ratio, the agent’s presence in the general therapy of this symptom can be underlined.

University and Doctoral School

Semmelweis University, Doctoral School of Theoretical and Translational Medicine

Supervisor

Dezső Csupor

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6834

Start

13:15

End

13:20

Authors (legacy)

Dénes Kleiner1;2, István Horváth1;2, Stefania Bunduc2;3;4;5;6, Dorottya Gergő2;7, Katalin Lugosi2, Peter Fehérvári2;8, Peter Hegyi2;3;4;9, Tamás Horváth2, Dezső Csupor2;10;11
1 University Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary
2 Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
3 Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
4 Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
5 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
6 Fundeni Clinical Institute, Bucharest, Romania
7 Department of Pharmacognosy, Semmelweis University, Budapest, Hungary
8 University of Veterinary Medicine, Budapest Dept. Of Biomathematics and Informatics, Budapest, Hungary
9 János Szentágothai Research Center, University of Pécs, Pécs, Hungary
10 Department of Clinical Pharmacy, University of Szeged, Szeged, Hungary
11 Department of Pharmacognosy, University of Szeged, Szeged, Hungary